-Advertisement-
-Advertisement-
Glaucoma
Glaukos submits new drug application to FDA for iDose TR
Glaukos has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time. iDose TR is intended to address...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Videos
-Advertisement-
-Advertisement-
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved